Peer-reviewed veterinary case report
Comparing chemo regimens for stem cell transplant in young
By Gupta AK et al.·2025·Department of Pediatrics (Division of Pediatric Oncology), India·View original on Europe PMC →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: Busulfan and melphalan (Bu-Mel) versus carboplatin, etoposide, and melphalan (CEM) conditioning regimens for autologous haematopoietic stem cell transplant in children and young adults with high-risk neuroblastoma.
Plain-English summary
This study looks at two different chemotherapy treatments before a stem cell transplant for children and young adults with high-risk neuroblastoma, a type of cancer. One treatment uses busulfan and melphalan, while the other combines carboplatin, etoposide, and melphalan. The goal is to see which treatment is more effective and safer for these young patients. The findings will help doctors choose the best approach for treating this serious condition.
Abstract
<h4>Objectives</h4>This is a protocol for a Cochrane Review (intervention). The objectives are as follows: To compare the efficacy and safety of busulfan and melphalan (Bu-Mel) conditioning chemotherapy with carboplatin, etoposide, and melphalan (CEM) conditioning chemotherapy for autologous haematopoietic stem cell transplantation in children and young adults (0 to 21 years of age) with high-risk neuroblastoma.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on Europe PMC: https://europepmc.org/article/MED/41231348